DOLEŽELOVÁ, Hana, Pavel ŠLAMPA, Barbora ONDROVÁ, Jana GOMBOŠOVÁ, Štěpánka SOVADINOVÁ, Tomáš NOVOTNÝ, Karol BOLČÁK, Jana RŮŽIČKOVÁ, Ludmila HYNKOVÁ a Marie FORBELSKÁ. The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study. Neoplasma. Slovakia: Slovak Academic Press Ltd., 2008, roč. 55, č. 5, s. 437-441. ISSN 0028-2685.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study
Název česky The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma - results of pilot study
Autoři DOLEŽELOVÁ, Hana (203 Česká republika, garant), Pavel ŠLAMPA (203 Česká republika), Barbora ONDROVÁ (203 Česká republika), Jana GOMBOŠOVÁ (203 Česká republika), Štěpánka SOVADINOVÁ (203 Česká republika), Tomáš NOVOTNÝ (203 Česká republika), Karol BOLČÁK (203 Česká republika), Jana RŮŽIČKOVÁ (203 Česká republika), Ludmila HYNKOVÁ (203 Česká republika) a Marie FORBELSKÁ (203 Česká republika).
Vydání Neoplasma, Slovakia, Slovak Academic Press Ltd. 2008, 0028-2685.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30200 3.2 Clinical medicine
Stát vydavatele Slovensko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 1.179
Kód RIV RIV/00216224:14110/08:00034039
Organizační jednotka Lékařská fakulta
UT WoS 000259468300011
Klíčová slova anglicky positron emission tomography;18-F-fluorodeoxyglucose;radiotherapy;cervical carcinoma
Štítky 18-F-fluorodeoxyglucose, cervical carcinoma, positron emission tomography, radiotherapy
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: RNDr. Marie Forbelská, Ph.D., učo 2120. Změněno: 29. 6. 2009 08:54.
Anotace
Positron emission tomography (PET) is used to distinguish between benign and malign tumors, to diagnose relapse or post-therapeutic changes. Lately, PET is used to predict the treatment response. and also a complementary method to determine target volumes in radiotherapy. Daily using of PET in the oncology praxis can change treatment strategy and improve its outcome. Results of this pilot study show the role of PET with 8-F-fluorodeoxyglucose (18FDG) for staging of cervical carcinoma and in the radiotherapeutic planning. Between March 2005 and May 2007, 51 patients with cervical carcinoma were treated with combination of external beam radiotherapy and HDR brachytherapy, with or without concomitant cisplatin. The lymphatic nodes treatment field size was determined by PET/CT fusion. Treatment results were evaluated by PET 3 and 9 months after treatment. The differences in the results of PET and CT were evaluated in this study. In 32 cases (62.75%) the results of PET and CT were identical, in 14 cases (27.45%) the nodal involvement was more extensive according to PET, in 5 cases (9.8%) the nodal involvement was more extensive according to CT. PET results 3 months after treatment were as follows: in 3 cases (5.88%) stable disease, in 35 cases (68.63 %) negative, in 4 cases (7.84%), progression of disease, in 3 cases (5.88 %) partial regression. There were no false positive results caused by inflammatory reaction persisting 3 months after radiotherapy, as was confirmed by repeating PET 9 months after treatment. The results of this study confirmed the important role of PET in diagnosis and treatment of cervical carcinoma and in determination of target volumes in radiotherapy. PET was found to be a standard staging examination of cervical carcinoma in Masaryk Memorial Cancer Institute. The predictive value of PET has not yet been validated. Key words: positron emission tomography, 18-F-fluorodeoxyglucose, radiotherapy, cervical carcinoma
Anotace česky
Positron emission tomography (PET) is used to distinguish between benign and malign tumors, to diagnose relapse or post-therapeutic changes. Lately, PET is used to predict the treatment response. and also a complementary method to determine target volumes in radiotherapy. Daily using of PET in the oncology praxis can change treatment strategy and improve its outcome. Results of this pilot study show the role of PET with 8-F-fluorodeoxyglucose (18FDG) for staging of cervical carcinoma and in the radiotherapeutic planning. Between March 2005 and May 2007, 51 patients with cervical carcinoma were treated with combination of external beam radiotherapy and HDR brachytherapy, with or without concomitant cisplatin. The lymphatic nodes treatment field size was determined by PET/CT fusion. Treatment results were evaluated by PET 3 and 9 months after treatment. The differences in the results of PET and CT were evaluated in this study. In 32 cases (62.75%) the results of PET and CT were identical, in 14 cases (27.45%) the nodal involvement was more extensive according to PET, in 5 cases (9.8%) the nodal involvement was more extensive according to CT. PET results 3 months after treatment were as follows: in 3 cases (5.88%) stable disease, in 35 cases (68.63 %) negative, in 4 cases (7.84%), progression of disease, in 3 cases (5.88 %) partial regression. There were no false positive results caused by inflammatory reaction persisting 3 months after radiotherapy, as was confirmed by repeating PET 9 months after treatment. The results of this study confirmed the important role of PET in diagnosis and treatment of cervical carcinoma and in determination of target volumes in radiotherapy. PET was found to be a standard staging examination of cervical carcinoma in Masaryk Memorial Cancer Institute. The predictive value of PET has not yet been validated. Key words: positron emission tomography, 18-F-fluorodeoxyglucose, radiotherapy, cervical carcinoma
VytisknoutZobrazeno: 26. 4. 2024 15:42